Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder.~* Patient's current depressive episode must be at least 12 weeks in duration~* Patient must have a parent or caregiver who must agree to accompany the patient to all clinic visits.~Exclusion Criteria:~* Patients who currently meet DSM-IV criteria for:~  1. attention deficit-hyperactivity disorder~ 2. obsessive-compulsive disorder~ 3. posttraumatic stress disorder~ 4. bipolar disorder~ 5. pervasive developmental disorder~ 6. mental retardation~ 7. conduct disorder~ 8. oppositional defiant disorder~* Patients who are considered a suicide risk (have active suicidal ideation), who have made a suicide attempt, or who have ever been hospitalized because of a suicide attempt.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): Escitalopram 10mg once daily for three weeks, 10-20mg once daily for up to the remaining 5 weeks
- 2 (Type: PLACEBO_COMPARATOR): Placebo once daily for up to 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).